middle.news
PYC Therapeutics Advances PKD Trial with Safety-Backed Dose Escalation
8:30am on Monday 24th of November, 2025 AEDT
•
Biotechnology
Read Story
PYC Therapeutics Advances PKD Trial with Safety-Backed Dose Escalation
8:30am on Monday 24th of November, 2025 AEDT
Key Points
Dose escalation approved for second cohort in Part B of Single Ascending Dose study
Safety Review Committee endorses continuation after positive 4-week safety data
PYC-003 targets the underlying cause of Polycystic Kidney Disease
Phase 1a/1b study progressing towards Open-Label Multiple Ascending Dose trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Pyc Therapeutics (ASX:PYC)
OPEN ARTICLE